Actelion Ltd. (ALIOF) Rating Lowered to Hold at Zacks Investment Research

Actelion Ltd. (OTCMKTS:ALIOF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “Actelion Limited is an independent, profitable, biopharmaceutical company discovering, developing and marketing drugs for high unmet medical needs. “

Shares of Actelion (OTCMKTS:ALIOF) opened at 172.60 on Wednesday. The company’s 50-day moving average price is $168.64 and its 200 day moving average price is $161.44. Actelion has a 12-month low of $122.00 and a 12-month high of $175.71. The firm has a market capitalization of $18.15 billion, a price-to-earnings ratio of 29.47 and a beta of 1.32.

About Actelion

Actelion Ltd is a Switzerland-based biopharmaceutical company that focuses on the discovery, development and commercialization of drugs for diseases with unmet medical needs. The Company specializes in the field of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.

Get a free copy of the Zacks research report on Actelion (ALIOF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Actelion Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actelion Ltd. and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.